Drugs / sigvotatug vedotin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06549816 | Aug 2024 → Nov 2025 | esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma +2 | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04389632 | Jun 2020 → Jun 2027 expected | Her2-receptor negative breast cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric neoplasm +8 | Pfizer | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07227298 | Jan 2026 → Mar 2029 expected | non-small cell lung carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06758401 | Jul 2025 → Sep 2028 expected | non-small cell lung carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT06012435 | Feb 2024 → May 2026 overdue | non-small cell lung carcinoma | Pfizer | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-22 | Pfizer | Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer pfizer.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sigvotatug vedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04389632 ↗ |
| Known as | SGN-B6A | “This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors.” NCT06549816 ↗ |
| Known as | Sigvotatug vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314879 ↗ |
| Known as | Sigvotatug vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314879 ↗ |
| Action | Deplete | “Sigvotatug vedotin (SV) is a medicine that works by binding to IB6 and delivering a toxic substance to kill cells.” PMID 41388832 ↗ Dec 2025 |
| Modality | Other / unclassified | “Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6.” NCT06549816 ↗ |
| Route | Intravenous | “Administered into the vein (IV; intravenously)” NCT04389632 ↗ |
| Target | ITGB6 | “Integrin beta-6 binding agent” CHEMBL5314879 ↗ |